In short. Tissue, biological and medicine pathways, and the gap that lets a product be lawful to prepare and supply while never being approved for cosmetic injection.
Key points
- A product can be lawful to prepare and supply while never having been approved for the use being sold.
- Rules that cover handling, donation and sterility are not the rules that establish benefit.
- A clinic can therefore be operating inside one set of requirements while making a claim that no requirement has tested.
A medicine has to be shown to work before it can be sold for a stated purpose. Cells and tissues have never been regulated in quite that way, because the framework developed for donated tissue used in transplantation, where the questions were safety and matching rather than a marketed indication. Cosmetic cell products live in the gap between the two.
Three routes
A product can be regulated as a medicine, in which case it needs an authorisation for a named indication supported by evidence. It can be regulated as a biological product, with requirements for characterisation, manufacturing and testing that vary between jurisdictions. Or it can be treated as a tissue or cell preparation, where the emphasis falls on donation, screening, handling and traceability rather than on proof of effect. Which route applies depends on the product and the market, and the same material can sit on different routes in different countries.
Where the gap opens
The tissue route was written for transfers that happen in a hospital, between a donor and a patient, for a clinical reason. A preparation made from a patient's own tissue and injected for a cosmetic purpose fits neither that picture nor the medicine picture. It is often described as minimally manipulated and for same day use, which is the language that keeps it outside the medicine pathway. What it then lacks is the thing the medicine pathway provides: an assessment that the product does what is claimed for the use it is being sold for.
Lawful and approved are different words
A product can be lawful to prepare and supply while never having been approved for the use being sold. Rules that cover handling, donation and sterility are not the rules that establish benefit. A clinic can therefore be operating inside one set of requirements while making a claim that no requirement has tested.
Enforcement, and why it varies
Regulators in several markets have issued statements that cell products offered for cosmetic use are unapproved, and some have taken action against specific clinics. Practice still varies widely, because enforcement depends on resources, on how a product is described and on whether a complaint is made. A reader should not assume that the absence of action means the absence of a rule. It more often means the rule has not been applied to that particular offering yet.
Three questions that belong with the regulator
- Is there an authorisation for this product for this use, and what does it name?
- Which route does the product sit on, and what does that route require to be shown?
- Has the regulator published anything about products of this kind for cosmetic use?
Regulation is not a guarantee of benefit, and its absence is not proof of harm. It is a statement about what has been assessed. In this field the assessments are mostly absent and the marketed claims are not, which is why the regulatory question is worth asking before the clinical one.
Frequently asked questions
What are the three regulatory routes a cell or tissue product can take?
A medicine, which needs an authorisation for a named indication backed by evidence; a biological product, with characterisation and manufacturing requirements that vary by market; or a tissue and cell preparation, where the emphasis is on donation, screening, handling and traceability.
How can a product be lawful and still unapproved for cosmetic injection?
Because the requirements that cover handling, donation and sterility are not the requirements that establish benefit. A product can satisfy one set of rules while carrying a claim that no assessment has tested for the use it is being sold for.
Does the lack of enforcement action mean the use is permitted?
No. Enforcement depends on resources, on how a product is described and on whether a complaint is made. Regulators in several markets have stated that cell products offered for cosmetic use are unapproved, and practice varies because the rule has not been applied everywhere.
Risks & Limitations
- Transplantation is established medicine for defined blood and immune conditions; the cosmetic products that borrow the name mostly hold no approval for injection.
- An unapproved cell or tissue preparation usually cannot be identified with certainty and cannot be dissolved, so a result that is unwanted or a lump that forms may not be correctable by an injection.
- Reported harms of unapproved cell and tissue injections include infection at the injection site, collections of pus requiring drainage, prolonged swelling, nodules that do not settle and granuloma formation.
- A preparation made at the point of care has no release testing that a regulator has reviewed, and the cell content of what is injected is often not measured.
- There is no randomised comparison of a stem cell facelift against a placebo or against an established treatment, and no agreed definition of the procedure for a trial to test.
When to Seek Care
- Spreading redness, warmth, fever or discharge from an injection site. Have it assessed by a clinician without delay.
- A firm lump, persistent pain, or skin that is changing colour weeks or months after an injection.
- Any change in vision, or severe pain around the eye, needs emergency care immediately.
- Contact the service that performed the treatment first, and then seek an assessment by somebody who can examine the area.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — procedure and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.